Therapeutics Against Influenza

Overview

Journal Curr Top Microbiol Immunol

Specialties Allergy & Immunology
Microbiology

Date 2012 Jan 17

PMID 22246228

Citations 15

Authors

Elena A Govorkova

Jonathan A McCullers

Affiliations

Soon will be listed here.

Abstract

Despite 75 years of research into prevention and treatment of influenza, the viruses that cause this disease continue to rank as some of the most important pathogens afflicting humans today. Progress in development of therapeutics for influenza has been slow for much of that time, but has accelerated in pace over the last two decades. Two classes of antiviral medications are used in humans at present, but each has limitations in scope and effectiveness of use. New strategies involving these licensed agents, including alternate forms of delivery and combination therapy with other drugs, are currently being explored. In addition, several novel antiviral compounds are in various clinical phases of development. Together with strategies designed to target the virus itself, new approaches to interrupt host-pathogen interactions or modulate detrimental aspects of the immune response have been proposed. Therapy for influenza will likely undergo substantial changes in the decades to come, evolving with our knowledge of pathogenesis as new approaches become viable and are validated clinically.

Citing Articles

Research trends and hotspots on global influenza and inflammatory response based on bibliometrics.

Li H, Zong Y, Li J, Zhou Z, Chang Y, Shi W Virol J. 2024; 21(1):313.

PMID: 39623458 PMC: 11613568. DOI: 10.1186/s12985-024-02588-4.

Type I Interferon Signaling Increases Versican Expression and Synthesis in Lung Stromal Cells During Influenza Infection.

Brune J, Chang M, Altemeier W, Frevert C J Histochem Cytochem. 2021; 69(11):691-709.

PMID: 34666527 PMC: 8554580. DOI: 10.1369/00221554211054447.

Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective.

Madsen A, Dai Y, McMahon M, Schmitz A, Turner J, Tan J Immunity. 2020; 53(4):852-863.e7.

PMID: 32976769 PMC: 7572813. DOI: 10.1016/j.immuni.2020.08.015.

The Cranberry Extract Oximacro Exerts Virucidal Activity Against Influenza Virus by Interfering With Hemagglutinin.

Luganini A, Terlizzi M, Catucci G, Gilardi G, Maffei M, Gribaudo G Front Microbiol. 2018; 9:1826.

PMID: 30131793 PMC: 6090095. DOI: 10.3389/fmicb.2018.01826.

Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies.

Dyall J, Gross R, Kindrachuk J, Johnson R, Olinger Jr G, Hensley L Drugs. 2017; 77(18):1935-1966.

PMID: 29143192 PMC: 5733787. DOI: 10.1007/s40265-017-0830-1.

References

Baz M, Abed Y, Papenburg J, Bouhy X, Hamelin M, Boivin G . Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med. 2009; 361(23):2296-7. DOI: 10.1056/NEJMc0910060. View

Ramisse F, Deramoudt F, Szatanik M, Bianchi A, Binder P, Hannoun C . Effective prophylaxis of influenza A virus pneumonia in mice by topical passive immunotherapy with polyvalent human immunoglobulins or F(ab')2 fragments. Clin Exp Immunol. 1998; 111(3):583-7. PMC: 1904895. DOI: 10.1046/j.1365-2249.1998.00538.x. View

Hurt A, Holien J, Parker M, Kelso A, Barr I . Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol. 2009; 83(20):10366-73. PMC: 2753113. DOI: 10.1128/JVI.01200-09. View

Moscona A, Porotto M, Palmer S, Tai C, Aschenbrenner L, Triana-Baltzer G . A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo. J Infect Dis. 2010; 202(2):234-41. PMC: 2891144. DOI: 10.1086/653621. View

Napolitano L, Park P, Raghavendran K, Bartlett R . Nonventilatory strategies for patients with life-threatening 2009 H1N1 influenza and severe respiratory failure. Crit Care Med. 2009; 38(4 Suppl):e74-90. DOI: 10.1097/CCM.0b013e3181cc5373. View

Webby R, Webster R . Are we ready for pandemic influenza?. Science. 2003; 302(5650):1519-22. DOI: 10.1126/science.1090350. View

Nguyen J, Hoopes J, Le M, Smee D, Patick A, Faix D . Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One. 2010; 5(2):e9332. PMC: 2825274. DOI: 10.1371/journal.pone.0009332. View

Stein D, Creticos C, JACKSON G, Bernstein J, Hayden F, Schiff G . Oral ribavirin treatment of influenza A and B. Antimicrob Agents Chemother. 1987; 31(8):1285-7. PMC: 174922. DOI: 10.1128/AAC.31.8.1285. View

Honda T, Kubo S, Masuda T, Arai M, Kobayashi Y, Yamashita M . Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en. Bioorg Med Chem Lett. 2009; 19(11):2938-40. DOI: 10.1016/j.bmcl.2009.04.067. View

10.

Smee D, Hurst B, Wong M, Bailey K, Bart Tarbet E, Morrey J . Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother. 2009; 54(1):126-33. PMC: 2798555. DOI: 10.1128/AAC.00933-09. View

11.

Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K . Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother. 2005; 49(3):981-6. PMC: 549233. DOI: 10.1128/AAC.49.3.981-986.2005. View

12.

Triana-Baltzer G, Gubareva L, Klimov A, Wurtman D, Moss R, Hedlund M . Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One. 2009; 4(11):e7838. PMC: 2770896. DOI: 10.1371/journal.pone.0007838. View

13.

Hayden F, Gubareva L, Monto A, Klein T, Elliot M, Hammond J . Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med. 2000; 343(18):1282-9. DOI: 10.1056/NEJM200011023431801. View

14.

McClellan K, Perry C . Oseltamivir: a review of its use in influenza. Drugs. 2001; 61(2):263-83. DOI: 10.2165/00003495-200161020-00011. View

15.

Dutkowski R, Smith J, Davies B . Safety and pharmacokinetics of oseltamivir at standard and high dosages. Int J Antimicrob Agents. 2010; 35(5):461-7. DOI: 10.1016/j.ijantimicag.2009.12.023. View

16.

OKeefe B, Smee D, Turpin J, Saucedo C, Gustafson K, Mori T . Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob Agents Chemother. 2003; 47(8):2518-25. PMC: 166092. DOI: 10.1128/AAC.47.8.2518-2525.2003. View

17.

Sugaya N, Ohashi Y . Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother. 2010; 54(6):2575-82. PMC: 2876358. DOI: 10.1128/AAC.01755-09. View

18.

Aldridge Jr J, Moseley C, Boltz D, Negovetich N, Reynolds C, Franks J . TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci U S A. 2009; 106(13):5306-11. PMC: 2664048. DOI: 10.1073/pnas.0900655106. View

19.

Hay A, Zambon M, Wolstenholme A, Skehel J, Smith M . Molecular basis of resistance of influenza A viruses to amantadine. J Antimicrob Chemother. 1986; 18 Suppl B:19-29. DOI: 10.1093/jac/18.supplement_b.19. View

20.

Bright R, Shay D, Shu B, Cox N, Klimov A . Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA. 2006; 295(8):891-4. DOI: 10.1001/jama.295.8.joc60020. View